[go: up one dir, main page]

HUP0103314A2 - Csökkentett gyomor-bélrendszeri toxicitású kamptotecinszármazékok alkalmazása - Google Patents

Csökkentett gyomor-bélrendszeri toxicitású kamptotecinszármazékok alkalmazása

Info

Publication number
HUP0103314A2
HUP0103314A2 HU0103314A HUP0103314A HUP0103314A2 HU P0103314 A2 HUP0103314 A2 HU P0103314A2 HU 0103314 A HU0103314 A HU 0103314A HU P0103314 A HUP0103314 A HU P0103314A HU P0103314 A2 HUP0103314 A2 HU P0103314A2
Authority
HU
Hungary
Prior art keywords
camptothecin derivatives
gastrointestinal toxicity
reduced gastrointestinal
sodium chloride
side effects
Prior art date
Application number
HU0103314A
Other languages
English (en)
Inventor
Magali Guffroy
Hervé Toutain
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9810043A external-priority patent/FR2782009B1/fr
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HUP0103314A2 publication Critical patent/HUP0103314A2/hu
Publication of HUP0103314A3 publication Critical patent/HUP0103314A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A találmány tárgya kamptotecinszármazékok alkalmazása gyomor-bélrendszeri mellékhatások nélkül vagy az ilyen mellékhatásokcsökkentésével. A találmány további tárgya nátrium-klorid-oldatokalkalmazása a kamptotecinszármazékok szedésével járó gyomor-bélrendszeri mellékhatások csökkentésére. Az alkalmazást az jellemzi,hogy a nátrium-kloridot vizes oldatban, orálisan adják be. A találmányszerinti módon alkalmazott kamptotecinszármazékok tumorellenes hatásúvegyületek. Ó
HU0103314A 1998-08-05 1999-08-03 Use of camptothecin derivatives, with reduced gastrointestinal toxicity HUP0103314A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9810043A FR2782009B1 (fr) 1998-08-05 1998-08-05 Utilisation de derives de la comptothecine, avec une toxicite gastro-intestinale reduite
US9631898P 1998-08-12 1998-08-12
PCT/FR1999/001916 WO2000007605A1 (fr) 1998-08-05 1999-08-03 Utilisation de derives de la camptothecine, avec une toxicite gastro-intestinale reduite

Publications (2)

Publication Number Publication Date
HUP0103314A2 true HUP0103314A2 (hu) 2002-01-28
HUP0103314A3 HUP0103314A3 (en) 2002-07-29

Family

ID=26234482

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103314A HUP0103314A3 (en) 1998-08-05 1999-08-03 Use of camptothecin derivatives, with reduced gastrointestinal toxicity

Country Status (24)

Country Link
US (1) US6476043B1 (hu)
EP (1) EP1102594B1 (hu)
JP (1) JP2002522392A (hu)
KR (1) KR20010072228A (hu)
AT (1) ATE217531T1 (hu)
AU (1) AU771195B2 (hu)
BG (1) BG64641B1 (hu)
CA (1) CA2340020A1 (hu)
CZ (1) CZ295775B6 (hu)
DE (1) DE69901506T2 (hu)
DK (1) DK1102594T3 (hu)
EA (1) EA002917B1 (hu)
EE (1) EE04264B1 (hu)
ES (1) ES2176009T3 (hu)
GE (1) GEP20043254B (hu)
HU (1) HUP0103314A3 (hu)
ID (1) ID27253A (hu)
IL (1) IL141232A0 (hu)
NO (1) NO20010454L (hu)
NZ (1) NZ509859A (hu)
PT (1) PT1102594E (hu)
SK (1) SK1732001A3 (hu)
TR (1) TR200100331T2 (hu)
WO (1) WO2000007605A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1189637E (pt) 1999-05-17 2007-01-31 Cancer Res Ventures Ltd Composições para melhorar a biodisponibilidade de fármacos administrados oralmente
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
ATE489094T1 (de) * 2004-02-13 2010-12-15 Yakult Honsha Kk Wässrige lösung mit einem camptothecin
US20050197355A1 (en) * 2004-03-02 2005-09-08 Henegar Kevin E. Compounds useful in preparing camptothecin derivatives
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
JP2006151950A (ja) * 2004-11-05 2006-06-15 Oto Corporation:Kk 納豆菌培養エキス含有製剤及び納豆菌培養エキスの保存方法
ATE446299T1 (de) * 2005-02-07 2009-11-15 Fermion Oy Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
WO2006084940A1 (en) * 2005-02-08 2006-08-17 Fermion Oy Process for producing [1,4'] bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof
US7767813B2 (en) * 2005-02-08 2010-08-03 Fermion Oy Preparation method
US7994186B2 (en) * 2005-04-18 2011-08-09 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284579A (en) * 1979-07-17 1981-08-18 The United States Of America As Represented By The Of The Department Of Health & Human Services (N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
CH663353A5 (de) * 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
CA1332413C (en) * 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
IT1247937B (it) * 1991-05-16 1995-01-05 Ist Naz Ric Sul Cancro Associazione farmaceutica ad attivita' antineoplastica
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
WO1996011005A2 (en) 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases

Also Published As

Publication number Publication date
IL141232A0 (en) 2002-03-10
TR200100331T2 (tr) 2001-07-23
ATE217531T1 (de) 2002-06-15
CZ2001382A3 (en) 2001-05-16
BG105216A (en) 2001-10-31
BG64641B1 (bg) 2005-10-31
AU771195B2 (en) 2004-03-18
DE69901506T2 (de) 2002-11-28
KR20010072228A (ko) 2001-07-31
NO20010454D0 (no) 2001-01-26
EA002917B1 (ru) 2002-10-31
WO2000007605A1 (fr) 2000-02-17
GEP20043254B (en) 2004-06-25
EE200100066A (et) 2002-06-17
ES2176009T3 (es) 2002-11-16
DE69901506D1 (de) 2002-06-20
EP1102594B1 (fr) 2002-05-15
EE04264B1 (et) 2004-04-15
PT1102594E (pt) 2002-10-31
DK1102594T3 (da) 2002-08-26
ID27253A (id) 2001-03-22
US6476043B1 (en) 2002-11-05
NO20010454L (no) 2001-01-26
CA2340020A1 (fr) 2000-02-17
JP2002522392A (ja) 2002-07-23
SK1732001A3 (en) 2001-06-11
CZ295775B6 (cs) 2005-11-16
AU5168799A (en) 2000-02-28
EP1102594A1 (fr) 2001-05-30
HUP0103314A3 (en) 2002-07-29
NZ509859A (en) 2003-09-26
EA200100214A1 (ru) 2001-08-27

Similar Documents

Publication Publication Date Title
TR200101335T2 (tr) İktidarsızlık tedavisi için pirazolopirimidinon türevleri
HUP0103314A2 (hu) Csökkentett gyomor-bélrendszeri toxicitású kamptotecinszármazékok alkalmazása
DK1071420T3 (da) Indolyl-3-glyoxylsyrederivater med antitumorvirkning
ATE124694T1 (de) Chinazolinderivate um die antitumorwirkung zu verbessern.
HK1079207A1 (en) Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
PT1157030E (pt) Complexos equinocandina/hidrato de carbono
YU75403A (sh) Vodeni amfotericin b preparat
TR200101719T2 (tr) Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı
DE60323529D1 (de) Rutheniumkomplexe mit antikrebswirkung
IL154755A0 (en) Antitumor theraphy comprising distamycin derivatives
NO970178D0 (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
PT1280527E (pt) Utilizacao de derivados de acriloil distamicina no tratamento de tumores associados a niveis de glutationa elevados
HUP0105359A2 (hu) Benzamidszármazékok és az azokat tartalmazó gyógyszerkészítmények
NO20010507L (no) Farmasoytisk sammensetning med antitumoraktivitet pa basis av karboplatin
RU2002129335A (ru) Ирригационный раствор для офтальмологии
DE60307103D1 (de) Platin-komplexe enhaltend chemisch modifizierte gallensäure mit antitumoraktivität
RU2002129336A (ru) Протектор роговицы
YU5301A (sh) Primena derivata kamptotecina sa smanjenom gastro-intestinalnom toksičnošću
UA81617C2 (en) Chalcone derivatives and their use
AR026384A1 (es) Composicion para la prevencion y el tratamiento de las enfermedades bucales, producto farmaceutico, kit que lo contiene, uso del mismo y metodo depreparacion

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): BELICZAY LASZLO, S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI IRODA, HU

Representative=s name: DR. LANG TIVADARNE, S.B.G. & K. SZABADALMI UEG, HU

FH92 Termination of representative

Representative=s name: BELICZAY LASZLO, S.B.G. & K. BUDAPESTI NEMZETK, HU

FD9A Lapse of provisional protection due to non-payment of fees